Capricor Therapeutics (CAPR) reported positive four-year data from its ongoing open-label extension trial of Deramiocel for Duchenne muscular dystrophy, showing reduced skeletal muscle disease progression and continued safety.

Patients experienced a median change of -0.5 points from baseline, suggesting that extended treatment with Deramiocel may help slow the disease progression over time, the company said Friday in a statement.

The therapy maintained a "favorable safety profile," the company said.

Despite the positive data, the company's shares fell 17% in recent Friday trading, paring earlier losses.

Price: 9.93, Change: -2.021, Percent Change: -16.83